Cases & Deals

GRA Venture Fund invests in Accuitis

Clients GRA Venture Fund, LLC and GRA Venture Fund (T.E.), LLC

Jones Day represented GRA Venture Fund, LLC and GRA Venture Fund (T.E.), LLC in connection with their purchase of Series A-2 Preferred Stock in a private placement by Accuitis, Inc., a clinical-stage biopharmaceutical company developing multiple first-in-class drug therapies to treat chronic, diseases of the skin and eye.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.